tirzepatide for fat loss Weight That Actually Works: Our In-Office Program: Envizion Medical: Wellness Center Tirzepatide for Medical Weight Loss

Emily Hart, Endocrinologist and Obesity Specialist

Over 25,000 clinical trial participants across SUSTAIN, PIONEER, STEP, SELECT programs

The ongoing, randomized, double-blind, placebo-controlled Phase 3 VISIONARY (NCT05248646) trial evaluated sibeprenlimab, administered SC every 4 weeks, for the treatment of adults with IgAN who are receiving maximally tolerated standard of care treatment. The primary endpoint was reduction of proteinuria as measured by the change in 24-hour urine protein-to-creatinine ratio (UPCR) at 9 months

Originally developed for type 2 diabetes management, higher-dose formulations (Wegovy) received FDA approval for chronic weight management in 2021

Adjustments or alternatives might help reduce symptoms

doi: 10.2337/dc17-1956 16 BrownEHeerspinkHJLCuthbertsonDJWildingJPH